Drugs / TMB-607
TMB-607
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03110549 | Nov 2016 → Jul 2019 | HIV infectious disease | TaiMed Biologics Inc. | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TMB-607 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03110549 ↗ |
| Known as | MK-8122 | ChEMBL registry synonym — accepted as the source's own label CHEMBL168640 ↗ |
| Known as | MX-100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL168640 ↗ |
| Known as | PL 100 (PHARMACEUTICAL) | ChEMBL registry synonym — accepted as the source's own label CHEMBL168640 ↗ |
| Known as | Pl-100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL168640 ↗ |
| Known as | PPL 100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL168640 ↗ |
| Modality | Small molecule | — CHEMBL168640 ↗ |
| Route | Intramuscular | “subcutaneous and intramuscular TMB-607” NCT03110549 ↗ |
| Route | Subcutaneous | “subcutaneous and intramuscular TMB-607” NCT03110549 ↗ |